8-KEarnings & ResultsExhibits & Filings

BIOGEN INC. 8-K Report, Financial Results (Jul 25, 2023)

Filed July 25, 2023For Securities:BIIB

Summary

Biogen Inc. (BIIB) filed an 8-K on July 25, 2023, to report its financial results for the second quarter ended June 30, 2023. The core of this filing is the accompanying press release (Exhibit 99.1), which details the company's performance during the quarter. Investors should review this press release for comprehensive updates on operational and financial conditions. While the 8-K itself does not contain the detailed financial data, it serves as the official notification that Biogen has publicly disclosed its Q2 2023 earnings. The press release, incorporated by reference, is the primary source for understanding revenue, profitability, product performance, and any forward-looking statements or strategic updates provided by the company. It's important to note that the information furnished under Item 2.02 is not considered 'filed' for certain regulatory purposes, meaning it doesn't carry the same liability as formally filed documents under Section 18 of the Exchange Act.

Key Highlights

  • 1Biogen Inc. announced its second quarter 2023 financial results on July 25, 2023, via an 8-K filing.
  • 2The filing incorporates by reference a press release (Exhibit 99.1) containing detailed results of operations and financial condition for the quarter ended June 30, 2023.
  • 3Investors are directed to the furnished press release for specific financial and operational performance data.
  • 4This 8-K filing serves as the official public disclosure mechanism for Biogen's Q2 2023 earnings.
  • 5Information furnished under Item 2.02 is not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934.

Frequently Asked Questions

The specific financial results for Biogen's second quarter ended June 30, 2023, are detailed in the press release (Exhibit 99.1) that is furnished as part of this 8-K filing. You will need to refer to that press release for the actual numbers regarding revenue, profitability, and other financial metrics.

This 8-K filing is significant because it officially announces that Biogen has released its earnings for the second quarter of 2023. It directs investors and the public to the accompanying press release for the detailed financial and operational performance information.

No, the press release furnished under Item 2.02 of this 8-K is specifically noted as not being 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934. This means it does not carry the same legal liabilities as documents that are formally filed with the SEC.